The effect of sitagliptin on myocardial performance in patients with type 2 diabetes and coronary artery disease.

Trial Profile

The effect of sitagliptin on myocardial performance in patients with type 2 diabetes and coronary artery disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Apr 2014

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Coronary artery disease; Left ventricular dysfunction; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 15 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top